RhumbLine Advisers’s Atea Pharmaceuticals AVIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $430K | Buy |
119,420
+2,977
| +3% | +$10.7K | ﹤0.01% | 2784 |
|
|
2025
Q1 | $348K | Sell |
116,443
-13,353
| -10% | -$39.9K | ﹤0.01% | 2799 |
|
|
2024
Q4 | $435K | Sell |
129,796
-3,318
| -2% | -$11.1K | ﹤0.01% | 2760 |
|
|
2024
Q3 | $446K | Sell |
133,114
-4,484
| -3% | -$15K | ﹤0.01% | 2772 |
|
|
2024
Q2 | $455K | Sell |
137,598
-4,304
| -3% | -$14.2K | ﹤0.01% | 2750 |
|
|
2024
Q1 | $573K | Sell |
141,902
-5,214
| -4% | -$21.1K | ﹤0.01% | 2578 |
|
|
2023
Q4 | $449K | Buy |
147,116
+12,808
| +10% | +$39.1K | ﹤0.01% | 2728 |
|
|
2023
Q3 | $403K | Sell |
134,308
-6,747
| -5% | -$20.2K | ﹤0.01% | 2738 |
|
|
2023
Q2 | $528K | Buy |
141,055
+17,368
| +14% | +$65K | ﹤0.01% | 2653 |
|
|
2023
Q1 | $414K | Buy |
123,687
+5,594
| +5% | +$18.7K | ﹤0.01% | 2501 |
|
|
2022
Q4 | $568K | Buy |
118,093
+1,979
| +2% | +$9.52K | ﹤0.01% | 2404 |
|
|
2022
Q3 | $661K | Buy |
116,114
+6,402
| +6% | +$36.4K | ﹤0.01% | 2368 |
|
|
2022
Q2 | $779K | Buy |
109,712
+27,475
| +33% | +$195K | ﹤0.01% | 2262 |
|
|
2022
Q1 | $594K | Sell |
82,237
-4,002
| -5% | -$28.9K | ﹤0.01% | 2345 |
|
|
2021
Q4 | $771K | Buy |
86,239
+547
| +0.6% | +$4.89K | ﹤0.01% | 2322 |
|
|
2021
Q3 | $3M | Buy |
85,692
+3,596
| +4% | +$126K | ﹤0.01% | 1661 |
|
|
2021
Q2 | $1.76M | Buy |
82,096
+64,933
| +378% | +$1.39M | ﹤0.01% | 2009 |
|
|
2021
Q1 | $1.06M | Buy |
17,163
+4,647
| +37% | +$287K | ﹤0.01% | 2167 |
|
|
2020
Q4 | $523K | Buy |
+12,516
| New | +$523K | ﹤0.01% | 2427 |
|